Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 320-326

  Kim, Jin Sun ^a   Kim, Jung Sun ^a   Kim, Tae Hoon ^a   Fan, Chunyu ^a   Lee, Jung Myung ^a   Kim, Woong ^b   Ko, Young Guk ^a   Choi, Donghoon ^a   Hong, Myeong Ki ^a   Jang, Yangsoo ^a  

^a Yonsei University Health System   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Drug eluting stent; Optical coherence; Paclitaxel; Sirolimus; Tomography

Indexed keywords

CYPHER SELECT; PACLITAXEL; RAPAMYCIN; TAXUS LIBERTE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; ANGIOGRAPHY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HUMAN; IMPLANTATION; INCIDENCE; INTIMA; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; STABLE ANGINA PECTORIS; THROMBUS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTHESIS DESIGN; REGISTRIES; SIROLIMUS; THROMBOSIS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 75749123502     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0546     Document Type: Article

References (31)

1. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159 - 168.
2. Salam AM, Al Suwaidi J, Holmes DR Jr. Drug-eluting coronary stents. Curr Probl Cardiol 2006; 31: 8 - 119.
3. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155: 108 - 113.
4. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M - 44M.
5. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333 - 342.
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435 - 2441.
7. Regar E, Schaar JA, Mont E, Virmani R, Serruys PW. Optical coherence tomography. Cardiovasc Radiat Med 2003; 4: 198 - 204.
8. Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlendorf KH, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106: 1640 - 1605.
9. Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: Comparison with intravascular ultrasound. J Am Coll Cardiol 2002; 39: 604 - 609.
10. Yamaguchi T, Terashima M, Akasaka T, Hayashi T, Mizuno K, Muramatsu T, et al. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol 2008; 101: 562 - 567.
11. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 2007; 99: 1033 - 1038.
12. Honda Y. Drug-eluting stents. Insights from invasive imaging technologies. Circ J 2009; 73: 1371 - 1380.
13. Barlis P, Dimopoulos K, Tanigawa J, Dzielicka E, Ferrante G, Del Furia F, et al. Quantitative analysis of intracoronary optical coherence tomography measurements of stent strut apposition and tissue coverage. Int J Cardiol 2009 Jan 18 [Epub ahead of print].
14. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol 2009; 134: 180 - 188.
15. Tanigawa J, Barlis P, Dimopoulos K, Di Mario C. Optical coherence tomography to assess malapposition in overlapping drug-eluting stents. EuroInterv 2008; 3: 580 - 583.
16. Chen BX, Ma FY, Luo W, Ruan JH, Xie WL, Zhao XZ, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 2008; 94: 566 - 570.
17. Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006; 97: 1713 - 1717.
18. Kim JS, Jang IK, Kim JS, Kim TH, Takano M, Kume T, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9 month follow up: Comparison with Sirolimus-eluting stents. Heart 2009; 95: 1907 - 1912.
19. Wessely R, Schomig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: Similar but different. J Am Coll Cardiol 2006; 47: 708 - 714.
20. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer 2000; 88: 2619 - 2628.
21. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003; 107: 2178 - 2180.
22. Iakovou I, Schmidt T, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, et al. Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. J Am Coll Cardiol 2005; 45: 805 - 806.
23. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663 - 670.
24. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653 - 662.
25. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006; 295: 895 - 904.
26. Rittersma SZ, de Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol 2004; 93: 477 - 480.
27. Buch AN, Waksman R. Cypher versus Taxus: All smoke and no fire: Lessons for future comparative drug-eluting stent trials in interventional cardiology. Am J Cardiol 2007; 99: 424 - 427.
28. Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. JACC Cardiovasc Interv 2009; 2: 453 - 458.
29. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, et al. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J 2009; 73: 1033 - 1037.
30. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, et al. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol 2009 Aug 24 [Epub ahead of print].
31. Murakami D, Takano M, Yamamoto M, Inami S, Ohba T, Seino Y, et al. Advanced neointimal growth is not associated with a low risk of in-stent thrombus: Optical coherence tomographic findings after first-generation drug-eluting stent implantation. Circ J 2009; 73: 1627 - 1634.